Skip to main content
Equibles

SHFH · Scientist Home Future Health Ltd · Metrics

Track SHFH — free

Use SHFH with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SHFH.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.70 At close · Oct 5
Rebalance outlook locked
Going-concern doubt — flagged Aug 11, 2026

Substantial doubt about the company's ability to continue as a going concern.

“For the six months ended June 30, 2026, the Company incurred a net loss of $199,924 and net current liabilities of $214,975. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. In addition, the Company’s independent registered public accounting firm, in its report on the Company’s December 31, 2025 financial statements, has expressed substantial doubt about the Company’s ability to continue as a going concern.”
View the 10-Q filed Aug 11, 2026
Market Cap
$40.32M
Shares
23.72M
Volume · Oct 5 333 Avg daily vol (28 sessions) 14.18K

SHFH metrics

42 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.70
Market cap
$40.32M

Price action

20 metrics
Price change (1W)
-2.9%
Price change (30D)
-76.1%
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
—
Annualized volatility (3M)
—
Beta
—
RSI (14D)
33.9
Price vs SMA 50
—
Price vs SMA 200
—
Avg volume (3M)
14,182
Relative volume
0.0
Average dollar volume
$108,771

Company

3 metrics
Sector
Healthcare
Industry
Pharmaceutical Retailers
Shares outstanding
23.72M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
101.0×
reciprocal yield 1.0%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-1.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
34.3%
Operating margin
-100.3%
Trailing 12 months
Net margin
-100.3%
Gross profit (TTM)
$136,836
Operating profit (TTM)
−$400,495
Net income (TTM)
−$400,495
Trailing 12 months
Diluted EPS (TTM)
$-0.01
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.02
Gross profit per diluted share (TTM)
$0.01
Operating profit per diluted share (TTM)
$-0.02
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-0.02
Operating cash flow per diluted share (TTM)
$-0.01
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.00

Growth

11 metrics
Revenue growth YoY
+162.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
$399,313
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+0.9%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-75.6%
Debt / equity
—
Current ratio
0.4
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
0.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$9,047
Latest balance sheet
Cash & equivalents
$9,047
Total assets
$529,844
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$322,808
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
$537,331
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
19 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 2032609 CUSIP 808925101 Visit website